Skip to main content

News

| Press release
Determine the right dose using genetic information — bio.logis collaborates with KNMP, the Royal Dutch Pharmacists Association

Based on the KNMP’s (Royal Dutch Pharmacists Association) latest pharmacogenetics insights, the G-Standaard drug database provides dosage recommendations for active ingredients depending on various genotypes. This enables Dutch physicians and patients to always access the most relevant information on the kind and dosage of drugs that will work best in each individual case. This service is now also available to users of the bio.logis Genetic Information Management Suite (GIMS): Laboratories and hospitals can incorporate this information directly in their pharmacogenetics reports. The partners have already signed a license agreement, allowing GIMS to directly retrieve select data from G-Standaard dosage recommendations — regardless of the country where GIMS is being used.

read more >
| Press release
Determine the right dose using genetic information — bio.logis collaborates with KNMP, the Royal Dutch Pharmacists Association

Dosage recommendations of the G-Standaard, a globally unique drug database owned by KNMP’s subsidiary Z-Index, are made internationally available by bio.logis via its Genetic Information Management Suite (GIMS) / license agreement signed / first user will be the German hospital Robert-Bosch-Krankenhaus Stuttgart

Based on the KNMP’s (Royal Dutch Pharmacists Association) latest pharmacogenetics insights, the G-Standaard drug database provides dosage recommendations for active ingredients depending on various genotypes. This enables Dutch physicians and patients to always access the most relevant information on the kind and dosage of drugs that will work best in each individual case. This service is now also available to users of the bio.logis Genetic Information Management Suite (GIMS): Laboratories and hospitals can incorporate this information directly in their pharmacogenetics reports. The partners have already signed a license agreement, allowing GIMS to directly retrieve select data from G-Standaard dosage recommendations—regardless of the country where GIMS is being used.

How effective a drug is, also depends on the patient’s genetic make-up, i.e., their genotype. Collecting this knowledge and making it widely available is one of KNMP´s key functions. To be able to do this, the Dutch Pharmacogenetics Working Group meets regularly to discuss new recommendations and updates. This data is incorporated in the so-called G-Standaard, a unique drug database going back to 1984 with monthly updates.

Having signed a license agreement with Z-Index, bio.logis can now make select information available to laboratories and hospitals via its Genetic Information Management Suite (GIMS). This is a valuable addition to bio.logis GIMS, the first platform of its kind to largely automatically deliver diagnostic reports on a patient’s genetic analysis results—based on a particular genotype, GIMS users can now include the right dosage recommendations in their laboratory reports even beyond the Dutch border.

In clinical practice the central role of a person´s genotype regarding the efficacy of drugs is still widely underestimated,” says Prof. Dr. med. Daniela Steinberger, Medical Director of bio.logis Genetic Information Management GmbH. “The agreement with Z-Index, enabling physicians to access dosage recommendations via our Genetic Information Management Suite, is an advancement for drug therapy,” adds Enrico Just, Managing Director, bio.logis GIM GmbH.

KNMP and bio.logis have been collaborating closely since 2016 within the framework of the EU-funded Ubiquitous Pharmacogenomics (U-PGx) project. U-PGx aims to expand the use of pharmacogenetics insights in daily clinical practice across Europe. That is why data from the G-Standaard database are incorporated into the EU project. bio.logis GIMS users now also benefit from this comprehensive data pool.

One of the first users of the service will be the German hospital Robert-Bosch-Krankenhaus Stuttgart (RBK), where bio.logis will implement its Genetic Information Management Suite with special data access to G-Standaard within the next few months and integrate it via existing interfaces with current RBK workflows. As of now, this service is available to all institutions, laboratories and hospitals.

About bio.logis Genetic Information Management GmbH

bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com.

Press Relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 31
maike.post@biologis.com 

Manuela Rost-Hein
Ketchum Pleon

c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com

| Article
Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects

Sehr viel mehr Menschen sterben an unerwünschten Wirkungen von Medikamenten als im Straßenverkehr. Mit der Zahl der Arzneien, die jemand einnimmt, steigt das Risiko dramatisch. Was aber, wenn selbst die Ärzte nicht weiterwissen?

read more >
| Article
Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects

Drugs do not have the same effect in all patients. Because so many factors affect drug response, doctors must choose a drug appropriate for each person and must adjust the dose carefully. This process is more complex if the person takes other drugs and has other diseases, because drug-drug and drug-disease interactions are possible.

Sehr viel mehr Menschen sterben an unerwünschten Wirkungen von Medikamenten als im Straßenverkehr. Mit der Zahl der Arzneien, die jemand einnimmt, steigt das Risiko dramatisch. Was aber, wenn selbst die Ärzte nicht weiterwissen?

Read whole article:

| Article
Article on "Personalized Medicine" in Plattform Life Science

Seit jeher versuchen Mediziner, ihren Patienten die bestmögliche Behandlung zukommen zu lassen. Doch ist der Mensch ein kompliziertes Wesen, will sagen, jeder Mensch reagiert anders auf die ihm verschriebene Dosis an Medikamenten oder Therapien. Ganz ähnlich verhält es sich mit den Krankheiten. Ursache, Verlauf oder Härtegrad hängen von einer Vielzahl von Faktoren ab. Dies bezieht sich nicht nur auf die genetische Ausstattung der Betroffenen, ihr Alter oder ihr Geschlecht. Auch externe Umwelteinflüsse und individuelle Lebensstile haben einen Einfluss. Die Folgen dieser Umstände sind maßgeblich, denn viele konventionell hergestellte Wirkstoffe erzielen längst nicht (mehr) die erhoffte Wirkung oder bringen nicht beabsichtigte Nebenwirkungen.

read more >
| Article
Article on "Personalized Medicine" in Plattform Life Science

Get an update on "Personalized Medicine" in an article written by Holger Garbs with quotations from our CEO Daniela Steinberger.

Seit jeher versuchen Mediziner, ihren Patienten die bestmögliche Behandlung zukommen zu lassen. Doch ist der Mensch ein kompliziertes Wesen, will sagen, jeder Mensch reagiert anders auf die ihm verschriebene Dosis an Medikamenten oder Therapien. Ganz ähnlich verhält es sich mit den Krankheiten. Ursache, Verlauf oder Härtegrad hängen von einer Vielzahl von Faktoren ab. Dies bezieht sich nicht nur auf die genetische Ausstattung der Betroffenen, ihr Alter oder ihr Geschlecht. Auch externe Umwelteinflüsse und individuelle Lebensstile haben einen Einfluss. Die Folgen dieser Umstände sind maßgeblich, denn viele konventionell hergestellte Wirkstoffe erzielen längst nicht (mehr) die erhoffte Wirkung oder bringen nicht beabsichtigte Nebenwirkungen.

Read more:

| Press release
German hospital Robert-Bosch-Krankenhaus Stuttgart and bio.logis GIM integrate pharmacogenetics into clinical practice—a milestone for personalized medicine

Personalized medicine is on everybody’s lips. For many patients it is a ray of hope because it promises better therapy and treatment results for the individual patient. Taking into account a patient’s genetic make-up is of particular importance here. Stuttgart’s Dr. Margarete Fischer-Bosch institute for clinical pharmacology (IKP) at the Robert-Bosch-Krankenhaus (RBK) is one of the leading pharmacogenetics institutions worldwide and works on how hereditary factors influence drug efficacy. Together with bio.logis GIM, a company based in Frankfurt, RBK will implement a newly developed IT platform (Genetic Information Management Suite, GIMS) and integrate it with its hospital information system using existing interfaces. GIMS enables RBK to automate the translation of its patients’ pharmacogenetic results into clinically exploitable therapy recommendations. For the first time, patients access their personal pharmacogenetic findings via a Web portal and use them for future medical treatment.

read more >
| Press release
German hospital Robert-Bosch-Krankenhaus Stuttgart and bio.logis GIM integrate pharmacogenetics into clinical practice—a milestone for personalized medicine

Implementation of the Genetic Information Management Suite (bio.logis) IT platform to automate report creation

Personalized medicine is on everybody’s lips. For many patients it is a ray of hope because it promises better therapy and treatment results for the individual patient. Taking into account a patient’s genetic make-up is of particular importance here. Stuttgart’s Dr. Margarete Fischer-Bosch institute for clinical pharmacology (IKP) at the Robert-Bosch-Krankenhaus (RBK) is one of the leading pharmacogenetics institutions worldwide and works on how hereditary factors influence drug efficacy. Together with bio.logis GIM, a company based in Frankfurt, RBK will implement a newly developed IT platform (Genetic Information Management Suite, GIMS) and integrate it with its hospital information system using existing interfaces. GIMS enables RBK to automate the translation of its patients’ pharmacogenetic results into clinically exploitable therapy recommendations. For the first time, patients access their personal pharmacogenetic findings via a Web portal and use them for future medical treatment.

“Why does some medication not work on certain patients?”, “Why do I experience side effects from a standard therapy?”—are questions often asked by patients. Stuttgart’s Dr. Margarete Fischer-Bosch institute for clinical pharmacology (IKP) has been working for many years on finding out the underlying causes. One focus is on pharmacogenetics, i.e., researching the influence of individual hereditary factors on drug efficacy. Prof. Matthias Schwab, IKP Director and professor for Clinical Pharmacology at the University of Tübingen, states: “For over 50 years, pharmacogenetics has been delivering excellent research and concepts for personalized medicine. We have now reached the point where we can systematically leverage this knowledge in Germany for the first time.”

Taking personal genetic analysis results into account in work routines easily and reliably and to gear hospital physicians’ therapy decisions towards it, is a topic that bio.logis GIM and its founder and Medical Managing Director, Prof. Daniela Steinberger, has been working on for many years. The human geneticist and her team have developed the Genetic Information Management Suite (GIMS) software solution that is capable of translating pharmacogenetic results into easily understood and specific recommendations for physicians in mere seconds.

The entire process is based on international guidelines. “Providing human genetics diagnostics reports is a complex process, requiring a high level of expertise; but it is hardly standardized yet,” says Prof. Daniela Steinberger, bio.logis GIM. “Patients can now be recommended to adjust their drug dose if, for example, they are missing a certain enzyme due to their genetic make-up. Straightforward therapy instructions can put treating physicians in a position to better categorize and reduce the risk of adverse side effects and therapy discontinuation,” adds Schwab.

The GIMS software, which complies with data protection regulations, is to be linked to RBK’s hospital information system and IKP’s genotyping platform in the next few months to integrate it with the existing work routine of RBK physicians. If the treating physician chooses pharmacogenetic diagnostics, a blood sample for analysis at the IKP is taken from the patient after obtaining their written consent as stipulated by the German Genetics Testing Law. The pharmacogenetics report generated by GIMS results in a recommendation to be used by the treating physician for their final choice of the correct dose for individual patients.

What makes GIMS so special: All patients can access their own pharmacogenetics reports online via a Web portal or mobile apps and make them available to physicians regardless of where they are based. “This allows the direct use of pharmacogenetics information also for future medical treatments, whether you are in Germany or abroad,” says Schwab.

“We are very happy to have won a renowned partner in RBK and a comrade-in-arms in IKP’s Mr Professor Schwab as a leading influencer in pharmacogenetics. The pharmacogenetic diagnostics concept now launched at RBK embodies the idea of personalized medicine with a comprehensive end-to-end solution for individual patients,” stresses Enrico Just, Managing Director, bio.logis GIM GmbH.
 

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. 
For more information about our company and our products, please visit www.biologis.com

Robert-Bosch-Krankenhaus
Stuttgart’s Robert-Bosch-Krankenhaus (RBK) is a hospital funded by the Robert Bosch foundation for centralized treatment with functions for maximum treatment three locations. Since 1978 the Robert-Bosch-Krankenhaus has been an academic teaching hospital of the University of Tübingen. With 1,031 beds, RBK, its sites Charlottenhaus clinic and Schillerhöhe clinic as well as the clinic for geriatric rehabilitation, have over 44,000 in-patients per year. Around 2,700 men and women ensure that RBK’s patients receive personalized nursing care. The hospital has 22 specialist departments in its centers for internal, surgical and diagnostic medicine and in its center for pneumology and thorax surgery, the Irmgard Bosch educational center, the institute for medical history and the Dr. Margarete Fischer-Bosch institute for clinical pharmacology.
www.rbk.de

The Dr. Margarete Fischer-Bosch institute for clinical pharmacology
The Dr. Margarete Fischer-Bosch institute for clinical pharmacology at the Robert Bosch hospital is one of the leading pharmacogenetics institutions worldwide and works on how hereditary factors influence drug efficacy. Collaborating with national and international partners, including the Tübingen university hospital and the German Cancer Research Center in Heidelberg, the focus is on pharmacogenetics and cancer research. 
All departments of the Robert-Bosch-Krankenhaus closely work with the Dr. Margarete Fischer-Bosch institute for clinical pharmacology. The insights gained from this collaboration are used directly in further training of nursing staff and physicians.

www.ikp-stuttgart.de
www.rbk.de

Press contacts:

Dr. Maike Post 
bio.logis Genetic Information Management GmbH 
Altenhöferallee 3 
D-60438 Frankfurt am Main 
Phone: +49 (0) 69 3487391 31 
maike.post@biologis.com 

Marlies Kepp
Robert-Bosch-Krankenhaus
Auerbachstraße 110
D-70376 Stuttgart
Phone +49 (0) 8101 3047
marlies.kepp@rbk.de

Manuela Rost-Hein 
Ketchum Pleon 
c/o Torstrasse 140 
D-10119 Berlin 
Phone: +49 (0) 30 400 54 752 
manuela.rost-hein@ketchumpleon.com
 

| Press release
Personalized medicine: Medical University of Vienna (MUW) to collaborate with bio.logis GIM in pharmacogenetics

Within the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna (MUW) will implement the Genetic Information Management Suite (GIMS) developed by bio.logis Genetic Information Management GmbH. The platform is the first of its kind to largely automatically translate genetic analysis results from laboratories into easily understood diagnostic reports, including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). Here, the MUW uses the Diagnostic Report Module (GIMS.DRM) in combination with a QR-based safety code card, developed by MUW, for patients. This card is used to make patients’ personal analysis results accessible.

read more >
| Press release
Personalized medicine: Medical University of Vienna (MUW) to collaborate with bio.logis GIM in pharmacogenetics

MUW will implement bio.logis Genetic Information Management Suite (GIMS) / platform for the automatic creation and online display of diagnostic reports and treatment recommendations / safety code card for patients

Within the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna (MUW) will implement the Genetic Information Management Suite (GIMS) developed by bio.logis Genetic Information Management GmbH. The platform is the first of its kind to largely automatically translate genetic analysis results from laboratories into easily understood diagnostic reports, including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). Here, the MUW uses the Diagnostic Report Module (GIMS.DRM) in combination with a QR-based safety code card, developed by MUW, for patients. This card is used to make patients’ personal analysis results accessible.

There is still far more scope in medical practice to use pharmacogenetic insights. The EU-funded project Ubiquitous Pharmacogenomics (U-PGx) would like to support this because pharmacogenetics enables important progress in personalized medicine. As a key partner of the U- PGx project, bio.logis GIM has implemented its Genetic Information Management Suite (GIMS) at selected university hospitals and institutions in various European countries, including the Medical University of Vienna.

bio.logis and MUW have now agreed to offer the safety code cardan emergency card for patients, the size of a credit cardbeyond the scope of the U-PGx project. A QR code printed on the card gives patients an easy and quick access to a web portal which provides dosing recommendations based on the patient ́s genetic analysis. These recommendations will support the attending physician in prescribing the right medication in the right dosage.

“Within the framework of U-PGx, the bio.logis Genetic Information Management Suite enables us to automate and speed up the creation and delivery of easily understood genetic-diagnostic reports,” says Assoc.-Prof. Matthias Samwald, MUW, who is also one of the U-PGx project leaders. “We will offer the products jointly developed during our cooperation also outside of this project.”

bio.logis GIMS works with pre-configured standardized expert knowledge. With the system’s Diagnostic Report Module (GIMS.DRM), creating a genetic-diagnostic report is done in a matter of seconds. An enormous time and cost saver, compared to traditional methods. The Delivery Module (GIMS.DM) can then be used by authorized physicians or the patients themselves to fetch these reports. The safety code card supplements the information for the patients.

“Our expert team, consisting of experienced specialists in human genetics diagnostics, biologists and IT professionals, has developed bio.logis GIMSa software platform using special algorithms, workflows and modular components for creating genetic-diagnostics reports and making them available at the point of care in very short time,” emphasizes Prof. Daniela Steinberger, Medical Managing Director, bio.logis GIM.

One of the most important considerations for bio.logis in every development is the security and protection of personal data. The system itself processes exclusively pseudonymized analysis data. Every communication channel is generally encrypted. This ensures that the allocation of analysis results to individuals can only be done by the responsible medical staff within the clinic. bio.logis complies with existing data security regulations including the EU-wide General Data Protection Regulation (GDPR), coming into force on May 25, 2018.

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and
makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com/.

Press Relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH

Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 31

maike.post@biologis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752

manuela.rost-hein@ketchumpleon.com

| Article
bio.logis GIM on GenomeWeb

An article about bio.logis GIM's distribution agreement with PGS.Holland for GenomeWeb:

Bio.logis, PGS.Holland Ink Distribution Pact for Genetic Diagnosis Software
NEW YORK (GenomeWeb) – Bio.logis Genetic Information Management and PGS.Holland have entered into an agreement to market Bio.logis' Genetic Information Management Suite (GIMS) in Belgium, the Netherlands, and Luxembourg (Benelux), Scandinavia, and the UK.

read more >
| Article
bio.logis GIM on GenomeWeb

Find here a short article about our distribution agreement with PGS.Holland for GenomeWeb.

Bio.logis, PGS.Holland Ink Distribution Pact for Genetic Diagnosis Software
NEW YORK (GenomeWeb) – Bio.logis Genetic Information Management and PGS.Holland have entered into an agreement to market Bio.logis' Genetic Information Management Suite (GIMS) in Belgium, the Netherlands, and Luxembourg (Benelux), Scandinavia, and the UK.

Read full text:

| Press release
bio.logis GIM GmbH concludes a distribution agreement with PGS.Holland BV

bio.logis Genetic Information Management (GIM) and PGS.Holland, have entered into a distribution collaboration to market the Genetic Information Management Suite (GIMS) in Benelux countries, Scandinavia, and the UK.

read more >
| Press release
bio.logis GIM GmbH concludes a distribution agreement with PGS.Holland BV

bio.logis GIM representation in the Netherlands / Strengthening of EU market activities

bio.logis Genetic Information Management (GIM) and PGS.Holland, have entered into a distribution collaboration to market the Genetic Information Management Suite (GIMS) in Benelux countries, Scandinavia, and the UK. This strategic partnership will bundle the expertise of both players in the genetic diagnostics laboratory market.

“With PGS.Holland we have won a partner with excellent knowledge and contacts in human genetics laboratory diagnostics,” says Enrico Just, CEO, bio.logis GIM. “Together, we will be able to provide genetic laboratories with even more targeted information and with the IT-based solutions for harmonizing and automating their highly manual diagnostic report processes.”

“We are very happy about our collaboration with bio.logis GIM. It will underline our long and proven track record in genetic diagnostics,” says Ronald Jager, Managing Director, PGS.Holland.

For now, PGS.Holland will use the experience gained during a variety of pharmacogenetic projects to concentrate on marketing GIMS.pharma in the recently opened up EU markets. GIMS.pharma is a “pharmacogenetic end-to-end product” developed by bio.logis GIM, for easy and quick plug-and-play integration with any diagnostic laboratory system.

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com/.

Press relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 31
maike.post@biologis.com

Dr. Carolin Nowak
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 44
carolin.nowak@biologis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com

| Article
bio.logis GIM on GenomeWeb

An article about bio.logis GIM by Justin Petrone for GenomeWeb:

Bio.logis Readies New Clinical Genetic Data Interpretation Tools Amid Growing Customer Interest
NEW YORK (GenomeWeb) – Bio.logis, a Frankfurt, Germany-based informatics company, is planning multiple upgrades to its flagship clinical genetic data interpretation tool as it continues to win new customers across Europe. CMO Maike Post said that the firm will launch two new analysis modules for its Genetic Information Management Suite next year, in addition to a new pharmacogenomics mobile application.

read more >
| Article
bio.logis GIM on GenomeWeb

Find here a very informative and interesting article about our company, our products and visions by Justin Petrone for GenomeWeb.

Bio.logis Readies New Clinical Genetic Data Interpretation Tools Amid Growing Customer Interest
NEW YORK (GenomeWeb) – Bio.logis, a Frankfurt, Germany-based informatics company, is planning multiple upgrades to its flagship clinical genetic data interpretation tool as it continues to win new customers across Europe. CMO Maike Post said that the firm will launch two new analysis modules for its Genetic Information Management Suite next year, in addition to a new pharmacogenomics mobile application. The activity is synchronous with uptake of Bio.logis' analytical tools at a number of laboratories. Last week the firm announced that Laboratoires Réunis, a medical analysis laboratory based in Luxembourg, had adopted GIMS to automate the creation of diagnostic reports. The firm's tools are also being used within the Ubiquitous Pharmacogenomics Consortium, a multinational, EU-funded project for the clinical implementation of pharmacogenetics.

Read full text:

| Press release
Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation.

read more >
| Press release
Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports

One of the largest private laboratories in Luxembourg uses the bio.logis Genetic Information Management Suite (GIMS) to automate the creation of extensive diagnostic reports

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation. 

With more than 50 blood sampling locations, a centralized laboratory in Junglinster, Luxembourg, as well as laboratory sites in Trier, Germany, and Fléron, Belgium, Laboratoires Réunis is one of the largest private laboratories in Luxembourg and considered to be a national pioneer for molecular diagnostics and personalized medicine. Apart from a broad spectrum of analyses in areas such as clinical chemistry or immunology, the Laboratoires Réunis group also offers a number of genetic analyses, a field in which it wants to expand further in future. In order to meet the challenges of efficiently producing high-quality clinical reports during these complex analyses, the lab’s scientists now use bio.logis GIM’s IT solution, specifically designed for this area of application. 

The starting point is the introduction of the software suite’s “Diagnostic Report Module (DRM)” to largely automate the creation of diagnostic reports on the basis of genetic analysis results. Using a centralized content management system for medical content ensures that the reports are also standardized and always up to date. DRM makes the reporting process highly efficient and improves its scalability. In addition, there are plans to successively introduce more Genetic Information Management Suite modules to further optimize existing processes. Both parties are also working on establishing individual functionalities of the Diagnostic Report Module so that other diagnostic fields also benefit from enhanced efficiency. 

“The Diagnostic Report Module is an enormous help for our scientific experts, who create complex reports on a daily basis,” says Dr Martin Schöndorf, Director Business Unit at Laboratoires Réunis, praising the collaboration with the men and women at bio.logis. “There is only one word to describe the support we received during the roll-out as well as the willingness and ability to adapt the solutions to our requirements and existing infrastructure—excellent.” Enrico Just, Managing Director, bio.logis GIM, adds: “We are very happy to have found a further renowned customer and reliable partner in Laboratoires Réunis, who also supports the improvement and evolution of our solutions with its own expertise and ideas.” 

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com/.

Press relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 31
maike.post@biologis.com

Dr. Carolin Nowak
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 44
carolin.nowak@biologis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com

| Article
bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

read more >
| Article
bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy

Decisions for drugs and active ingredients depending on genetic variants / Individual drug therapies are supported

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

The DNA of every person is unique, nobody completely equals another person. This also affects the metabolism of drugs. Back in the sixties, pharmacologists found out that various human genetic variants lead to different efficacy of certain drugs. Especially antibiotics, chemotherapeutics, HIV therapeutics, oral antidiabetics, psychotropic drugs or analgesics are metabolized differently. If genetic variants are taken into consideration, recommendations for adjusting the dose or prescribing an alternative therapy can be given.

A huge amount of information about genetic variants being important for many drugs couldn’t be used in the clinical practice so far because no supporting tools have been available. Therefore, bio.logis GIM developed the “pharma.sensor” app to check whether there exists relevant DNA information for the efficacy or rather tolerance of different drugs, respectively. If so, a genetic test can be considered.

With just a few clicks, such a genetic test can be ordered directly via the “pharma.sensor” app. For this purpose, the app links to the services of the bio.logis Center for Human Genetics, a specialist for genetic analyses. Other partners will be included in the future as well.

 

The “pharma.sensor” app is available via the Apple App Store and can be downloaded free of charge.
A version for Android will also be available soon.